Pharmacovigilance reports do show signals that have not been fully explained, and the question is not entirely settled
Referenced Citations Ahrn, B., et al., Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Patients and clinicians must therefore rely on theoretical considerations, individual patient factors, and clinical judgment
The Role of Professional Support in Long-Term Success Weight regain after GLP-1 discontinuation is significantly reduced when you maintain regular contact with a healthcare provider or registered dietitian, even if it's just quarterly check-ins
Remember that individual results may vary, and open communication with healthcare providers remains crucial in optimizing the long-term benefits of GLP-1 analogue therapies